Spark Therapeutics   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: Philadelphia PA United States (2013)
Status: Acquired by Roche (2019)

Organization Overview

First Clinical Trial
2013
NCT00516477
First Marketed Drug
2017
voretigene neparvovec (Luxturna)
First NDA Approval
2017
voretigene neparvovec (Luxturna)
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Spark Biomedical, Inc. | SPARK Biopharma | Spark Therapeutics | Spark Therapeutics, Inc.

Active Ingredients

Marketed Drugs (1)

voretigene neparvovec (Luxturna) (2017 NDA)

Drugs in Phase 3 Trials (1)

voretigene neparvovec (Luxturna) (3 trials)

Drugs in Phase 2 Trials (5)

aav2-hchm (1 trial)

spk-3006 (1 trial)

spk-8011 (1 trial)

spk-8016 (1 trial)

spk-9001 (1 trial)

Drugs in Phase 1 Trials (2)

aav8-hfix19 (1 trial)

sb17170 (2 trials)

Drugs in Other Trials (2)

lofexidine (lucemyra) (1 trial)

naltrexone (revia) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Blindness (Phase 3)

Blood Coagulation Disorders (Phase 2)

Blood Coagulation Disorders, Inherited (Phase 2)

Choroideremia (Phase 2)

Coagulation Protein Disorders (Phase 2)

Disease (Phase 2)

Genetic Diseases, Inborn (Phase 2)

Genetic Diseases, X-Linked (Phase 2)

Glycogen Storage Disease (Phase 2)

Glycogen Storage Disease Type II (Phase 2)

Hematologic Diseases (Phase 2)

Hemophilia A (Phase 2)

Hemophilia B (Phase 2)

Hemorrhagic Disorders (Phase 2)

Hemostatic Disorders (Phase 2)

Leber Congenital Amaurosis (Phase 3)

Lysosomal Storage Diseases (Phase 2)

Metabolic Diseases (Phase 2)

Retinal Dystrophies (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 12
  • # of Trial APIs: 10